Antifibrotic effect and long‐term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus

Antifibrotic effect and long‐term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus

Abstract The aim of this retrospective multicenter study was to clarify the antifibrotic effect and long‐term outcome of sodium glucose cotransporter 2 inhibitors (SGLT2‐Is) in patients with nonalcoholic fatty liver disease (NAFLD) complicated by type 2 diabetes mellitus (T2DM). Of the 1262 consecut...

Full description

Bibliographic Details
Main Authors: Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Shigeru Mikami, Uojima Haruki, Keiichiro Yoshikata, Hiroki Ono, Tadamichi Kawano, Yuji Yoshida, Tomohide Tanabe, Tomomi Okubo, Korenobu Hayama, Ai Nakagawa‐Iwashita, Norio Itokawa, Chisa Kondo, Keiko Kaneko, Mototsugu Nagao, Kyoko Inagaki, Izumi Fukuda, Hitoshi Sugihara, Katsuhiko Iwakiri
Format: Article
Language:English
Published: Wolters Kluwer Health/LWW 2022-11-01
Series:Hepatology Communications
Online Access:https://doi.org/10.1002/hep4.2069

Internet

https://doi.org/10.1002/hep4.2069

Similar Items